Clinical trials are experiments designed to test the safety and efficacy of new treatments or interventions in a controlled setting. The results of these trials are used to make decisions about whether or not to approve new drugs or treatments for use in the general population.
However, it’s important to recognize that the results of clinical trials may have limitations when it comes to their generalizability to the larger population. This is because clinical trials are typically conducted under controlled conditions, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Some of the limitations of clinical trial results in terms of generalizability to the larger population include:
Limited patient population: Clinical trials often have strict inclusion and exclusion criteria, which can limit the types of patients who are eligible to participate. This means that the results may not be generalizable to patients who do not meet these criteria.
Short follow-up time: Clinical trials are often conducted over a relatively short period of time, which may not be long enough to capture the long-term effects of the treatment or intervention.
Controlled setting: Clinical trials are conducted in a controlled setting, which may not accurately reflect the real-world conditions in which the treatment or intervention will be used.
Selective reporting [Controversial]: Clinical trial results may be subject to selective reporting, where only the most favorable outcomes are reported, while negative results are suppressed.
Real-world evidence (RWE) refers to data collected outside of clinical trials, such as data from electronic health records, insurance claims, and patient registries. RWE can provide important insights into how treatments or interventions work in real-world settings, and can help to address some of the limitations of clinical trial results in terms of generalizability.
However, it’s important to recognize that RWE also has its own limitations, such as the potential for confounding and bias, as well as issues related to data quality and completeness. Therefore, it’s important to carefully consider the limitations and potential biases of both clinical trial results and real-world evidence when making decisions about treatments or interventions for the larger population.
Share this story...
Real World Evidence (RWE) 101 – ‘Interventional’ Clinical Trial vs Non-Interventional Study
RWE 101 - 'Interventional' Clinical Trial vs Non-Interventional Study Interventional Clinical Trial: In this type of study, researchers actively intervene by assigning participants to different groups, administering specific treatments, [...]
Real World Evidence (RWE) 101 – Are the terms ‘clinical study’ and ‘clinical trial’ synonymous in the context of non-interventional studies?
RWE 101 - Are the terms 'clinical study' and 'clinical trial' synonymous in the context of non-interventional studies? No, "clinical study" and "clinical trial" are not necessarily synonymous in [...]
Real World Evidence (RWE) 101 – The Importance of Regulatory Definitions
RWE 101 - The Importance of Regulatory Definitions "Words are powerful"Regulatory definitions are important in the context of real-world evidence (RWE) studies and real-world research for several reasons:[1] Consistency: [...]
Real World Evidence (RWE) 101 – Regulatory Compliance
RWE 101 - Regulatory Compliance Regulatory compliance in the context of real-world evidence (RWE) refers to ensuring that the generation and use of RWE for regulatory purposes [...]
Real World Evidence (RWE) 101 – Regulatory Intelligence
RWE 101 - Regulatory Intelligence In the context of real-world evidence (RWE) and real-world research (RWR), regulatory intelligence refers to the process of gathering, analyzing, and interpreting regulatory information [...]
Real World Evidence (RWE) 101 – Regulatory Science
RWE 101 - Regulatory Science Regulatory science is a field of study that involves the application of scientific methods, principles, and data to the development and evaluation of regulatory [...]







